Most Important Outcomes Research Papers on Stroke and Transient Ischemic Attack

Each year in the United States, approximately 800 000 men and women are affected by stroke, which equates to one incident of stroke every 40 seconds.1 Stroke is the fourth leading cause of death nationally and is one of the foremost contributors to functional disability.2 The cost to the US healthcare system is substantial. Specifically, in 2010 medical treatment for stroke cost approximately $54 billion and is expected to exceed $1 trillion by 2050.3 The burden of stroke is not limited to US alone; mortality from stroke is responsible for ~9% of all deaths worldwide and is the second most common cause of death following ischemic heart disease.4 While the overall risk of stroke has declined by 25% in the last decade,5 disability from stroke is now emerging as a major public health problem, particularly in the elderly, as we observe an increase in aging of the population. Accordingly, in this month’s topic review in Circulation: Cardiovascular Quality and Outcomes , we concentrate on contemporary issues around stroke and transient ischemic attack (TIA). Significant knowledge and practice gaps continue to exist across the continuum of stroke care. First, risk factor modification for stoke remains suboptimal. The most important modifiable risk factor for prevention of stroke is hypertension (HTN), with the lowering of blood pressure associated with a more than 25% reduction in the relative risk (RR) of stroke.6,7 Modification of other risk factors such as diabetes, hypercholesterolemia, smoking cessation and atrial fibrillation (AF),8 have also been shown to reduce the incidence of stroke.9 However, appropriate identification of patients at risk and ensuring adherence to prevention strategies presents many challenges. For example, numerous patients with HTN are not on therapy and many of those who are treated have suboptimal blood pressure …

[1]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[2]  Douglas G Altman,et al.  Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses , 2003, BMJ : British Medical Journal.

[3]  D. Berlowitz,et al.  Hypertension control: how well are we doing? , 2003, Archives of internal medicine.

[4]  M. Kaste,et al.  Effectiveness of Primary and Comprehensive Stroke Centers: PERFECT Stroke: A Nationwide Observational Study From Finland , 2010, Stroke.

[5]  Adrian F Hernandez,et al.  Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke: Patient Characteristics, Hospital Factors, and Outcomes Associated With Door-to-Needle Times Within 60 Minutes , 2011, Circulation.

[6]  Eric E. Smith,et al.  Characteristics, Performance Measures, and In-Hospital Outcomes of the First One Million Stroke and Transient Ischemic Attack Admissions in Get With The Guidelines-Stroke , 2010, Circulation. Cardiovascular quality and outcomes.

[7]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[8]  H. Uno,et al.  Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  Eric E. Smith,et al.  Are Quality Improvements in the Get With The Guidelines-Stroke Program Related to Better Care or Better Data Documentation? , 2011, Circulation. Cardiovascular quality and outcomes.

[10]  Maurice Buchbinder,et al.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2009, The Lancet.

[11]  W. Baker,et al.  Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States , 2009, Journal of managed care pharmacy : JMCP.

[12]  A. Tonkin,et al.  Statins for stroke prevention: disappointment and hope. , 2004, Circulation.

[13]  V. Pavlik,et al.  Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. , 2000, Archives of internal medicine.

[14]  Keun-Hwa Jung,et al.  Secular Trends in Ischemic Stroke Characteristics in a Rapidly Developed Country: Results From the Korean Stroke Registry Study (Secular Trends in Korean Stroke) , 2012, Circulation. Cardiovascular quality and outcomes.

[15]  R E Latchaw,et al.  Recommendations for the establishment of primary stroke centers , 2000 .

[16]  R. Nelson,et al.  The cost-effectiveness of telestroke in the treatment of acute ischemic stroke , 2011, Neurology.

[17]  Jeffrey L Saver,et al.  The Impact of Recanalization on Ischemic Stroke Outcome: A Meta-Analysis , 2007, Stroke.

[18]  J. Broderick,et al.  Impact of Onset-to-Reperfusion Time on Stroke Mortality: A Collaborative Pooled Analysis , 2013, Circulation.

[19]  Gustavo Saposnik,et al.  IScore: A Risk Score to Predict Death Early After Hospitalization for an Acute Ischemic Stroke , 2011, Circulation.

[20]  J. Tu,et al.  Rhythm Versus Rate Control Therapy and Subsequent Stroke or Transient Ischemic Attack in Patients With Atrial Fibrillation , 2012, Circulation.

[21]  R. Sacco,et al.  Further good news on stroke, but no time for rest. , 2011, Circulation.

[22]  S Claiborne Johnston,et al.  Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling , 2009, The Lancet Neurology.

[23]  R. Sacco,et al.  Translating Evidence Into Practice: A Decade of Efforts by the American Heart Association/American Stroke Association to Reduce Death and Disability Due to Stroke: A Presidential Advisory From the American Heart Association/American Stroke Association , 2010, Stroke.

[24]  Sudha Seshadri,et al.  Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. , 2006, JAMA.

[25]  D. Bravata,et al.  Prevalence of Inadequate Blood Pressure Control Among Veterans After Acute Ischemic Stroke Hospitalization: A Retrospective Cohort , 2011, Circulation. Cardiovascular quality and outcomes.

[26]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[27]  P. Neužil,et al.  Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial , 2013, Circulation.

[28]  Li Liang,et al.  Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack , 2009, Circulation.

[29]  J. Saver,et al.  Declining Stroke and Vascular Event Recurrence Rates in Secondary Prevention Trials Over the Past 50 Years and Consequences for Current Trial Design , 2011, Circulation.

[30]  Richard Horton,et al.  GBD 2010: understanding disease, injury, and risk , 2012, The Lancet.

[31]  J. Avorn The relative cost-effectiveness of anticoagulants: obvious, except for the cost and the effectiveness. , 2011, Circulation.

[32]  D. Bravata,et al.  Use of Antithrombotic Medications Among Elderly Ischemic Stroke Patients , 2011, Circulation. Cardiovascular quality and outcomes.

[33]  H. Uno,et al.  Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa: The Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Experience , 2011, Circulation.

[34]  Jun Zhu,et al.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[35]  Eric E. Smith,et al.  Use of Tissue-Type Plasminogen Activator Before and After Publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-Stroke , 2012, Circulation. Cardiovascular quality and outcomes.

[36]  Jeffrey L Saver,et al.  Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. , 2009, Stroke.

[37]  Jeroen J. Bax,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[38]  J. Kluger,et al.  Cost-Effectiveness of Apixaban Compared With Aspirin for Stroke Prevention in Atrial Fibrillation Among Patients Unsuitable for Warfarin , 2012, Circulation. Cardiovascular quality and outcomes.

[39]  Scott Hamilton,et al.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.

[40]  Pamela W Duncan,et al.  Management of Adult Stroke Rehabilitation Care: a clinical practice guideline. , 2005, Stroke.

[41]  Sharon-Lise T. Normand,et al.  An Administrative Claims Measure Suitable for Profiling Hospital Performance on the Basis of 30-Day All-Cause Readmission Rates Among Patients With Heart Failure , 2008, Circulation. Cardiovascular quality and outcomes.

[42]  Eric E. Smith,et al.  Risk Score for In-Hospital Ischemic Stroke Mortality Derived and Validated Within the Get With The Guidelines–Stroke Program , 2010, Circulation.

[43]  Harlan M. Krumholz,et al.  An Administrative Claims Measure Suitable for Profiling Hospital Performance Based on 30-Day All-Cause Readmission Rates Among Patients With Acute Myocardial Infarction , 2011, Circulation. Cardiovascular quality and outcomes.

[44]  Geoff Cohen,et al.  Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis , 2012, The Lancet.

[45]  D. Singer,et al.  A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. , 2011, Journal of the American College of Cardiology.

[46]  A. Camm,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, European heart journal.

[47]  Eric E. Smith,et al.  Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines–Stroke Hospitals , 2013 .

[48]  S. Solomon,et al.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.

[49]  T. Meinertz,et al.  Event‐Recorder Monitoring in the Diagnosis of Atrial Fibrillation in Symptomatic Patients: Subanalysis of the SOPAT Trial , 2006, Journal of cardiovascular electrophysiology.

[50]  G. Lip,et al.  Added Predictive Ability of the CHA2DS2VASc Risk Score for Stroke and Death in Patients With Atrial Fibrillation: The Prospective Danish Diet, Cancer, and Health Cohort Study , 2012, Circulation. Cardiovascular quality and outcomes.

[51]  A. Verma,et al.  Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. , 2011, The Canadian journal of cardiology.

[52]  Sebastian Schneeweiss,et al.  Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial Fibrillation , 2012, Circulation. Cardiovascular quality and outcomes.

[53]  Harlan M Krumholz,et al.  An Administrative Claims Model Suitable for Profiling Hospital Performance Based on 30-Day Mortality Rates Among Patients With Heart Failure , 2006, Circulation.

[54]  Salim Yusuf,et al.  Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[55]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation , 2002 .

[56]  A. Torbicki,et al.  Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. , 2004, Chest.

[57]  Amanda H. Salanitro,et al.  Estimating and Reporting on the Quality of Inpatient Stroke Care by Veterans Health Administration Medical Centers , 2012, Circulation. Cardiovascular quality and outcomes.

[58]  D. Xavier,et al.  Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .

[59]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[60]  Mark D. Huffman,et al.  Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.

[61]  D. Packer,et al.  The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. , 2006, American heart journal.

[62]  S. Yusuf,et al.  Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy , 2012, Circulation.

[63]  Leandro Provinciali,et al.  Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .

[64]  Michal Abrahamowicz,et al.  Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. , 2005, American journal of epidemiology.

[65]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[66]  Eric E. Smith,et al.  Emergency Medical Service Hospital Prenotification Is Associated With Improved Evaluation and Treatment of Acute Ischemic Stroke , 2012, Circulation. Cardiovascular quality and outcomes.

[67]  R. Nogueira,et al.  “Picture to Puncture”: A Novel Time Metric to Enhance Outcomes in Patients Transferred for Endovascular Reperfusion in Acute Ischemic Stroke , 2013, Circulation.

[68]  D. Singer,et al.  Risks and Benefits of Anticoagulation in Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry , 2013, Circulation. Cardiovascular quality and outcomes.

[69]  Hardeep Singh,et al.  Quality of Care for Hypertension and Diabetes in Federal- Versus Commercial-Managed Care Organizations , 2004, American journal of medical quality : the official journal of the American College of Medical Quality.

[70]  L. Prokop,et al.  Endovascular therapy for acute ischemic stroke: a systematic review and meta-analysis. , 2013, Mayo Clinic proceedings.

[71]  J. McNeil,et al.  Greater Incidence of Both Fatal and Nonfatal Strokes in Disadvantaged Areas: The Northeast Melbourne Stroke Incidence Study , 2006, Stroke.

[72]  D. Bravata,et al.  Does the Inclusion of Stroke Severity in a 30-Day Mortality Model Change Standardized Mortality Rates at Veterans Affairs Hospitals? , 2012, Circulation. Cardiovascular quality and outcomes.

[73]  A. Tjønneland,et al.  Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: A population-based prospective cohort study of 57,053 men and women in Denmark , 2007, Scandinavian journal of public health.

[74]  P. Heuschmann,et al.  Effects of the implementation of a telemedical stroke network: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria, Germany , 2006, The Lancet Neurology.

[75]  Mårten Rosenqvist,et al.  Stepwise Screening of Atrial Fibrillation in a 75-Year-Old Population: Implications for Stroke Prevention , 2013, Circulation.

[76]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[77]  Eric E. Smith,et al.  Improving Door-to-Needle Times in Acute Ischemic Stroke: The Design and Rationale for the American Heart Association/American Stroke Association's Target Stroke Initiative , 2011, Stroke.

[78]  V. Feigin,et al.  Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review , 2009, The Lancet Neurology.

[79]  N. Ammash,et al.  Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: A transesophageal echocardiographics tudy , 1995 .

[80]  G. Diamond,et al.  Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: Section 1: diagnosis of stable ischemia and ischemic heart disease. , 2004, Circulation.

[81]  G. Saposnik,et al.  The iScore Predicts Functional Outcome in Korean Patients With Ischemic Stroke , 2013, Stroke.

[82]  M. Wintermark,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[83]  Alan D. Lopez,et al.  Mortality by cause for eight regions of the world: Global Burden of Disease Study , 1997, The Lancet.

[84]  R. de Caterina,et al.  Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation , 2013, Circulation.

[85]  R. Tamblyn,et al.  The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. , 1995, Journal of clinical epidemiology.

[86]  Harlan M Krumholz,et al.  Development, validation, and results of a measure of 30-day readmission following hospitalization for pneumonia. , 2011, Journal of hospital medicine.

[87]  Anthony S. Kim,et al.  Global Variation in the Relative Burden of Stroke and Ischemic Heart Disease , 2011, Circulation.

[88]  B. Popkin,et al.  The nutrition transition and obesity in the developing world. , 2001, The Journal of nutrition.

[89]  Jiaquan Xu,et al.  Deaths: final data for 2008. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[90]  J. Leonardi-Bee,et al.  Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events: A Systematic Review , 2003, Stroke.

[91]  Thomas Lumley,et al.  Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. , 2003, JAMA.

[92]  J. Switzer,et al.  Cost-Effectiveness of Hub-and-Spoke Telestroke Networks for the Management of Acute Ischemic Stroke From the Hospitals’ Perspectives , 2013, Circulation. Cardiovascular quality and outcomes.

[93]  Ning Zhang,et al.  External Validation of the iScore for Predicting Ischemic Stroke Mortality in Patients in China , 2013, Stroke.

[94]  Trends in Prevalence, Awareness, Treatment, and Control of Hypertension in the United States, 1988-2000 , 2003 .

[95]  Stephen Prudhomme,et al.  Revised and Updated Recommendations for the Establishment of Primary Stroke Centers: A Summary Statement From the Brain Attack Coalition , 2011, Stroke.

[96]  G. Schuler,et al.  Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. , 2007, Journal of the American College of Cardiology.

[97]  B. Gage,et al.  Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation , 2010, Circulation.

[98]  E. Peterson,et al.  Patterns of Emergency Medical Services Use and Its Association With Timely Stroke Treatment: Findings From Get With the Guidelines-Stroke , 2013, Circulation. Cardiovascular quality and outcomes.

[99]  S. Solomon,et al.  Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. , 2005, American heart journal.

[100]  A. Khera,et al.  Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association , 2011, Circulation.

[101]  S. Normand,et al.  An Administrative Claims Model Suitable for Profiling Hospital Performance Based on 30-Day Mortality Rates Among Patients With an Acute Myocardial Infarction , 2006, Circulation.